Exploiting the full width of the therapeutic window to salvage the ischemic penumbra: Imaging for cost-effective, personalized therapy

Functional Neurology

Volumn 21, Issue 4, 2006, Pages 181-185

  Bastianello, Stefano ^a   Del Sole, Angelo ^b   Bosone, Daniele ^c   Cavailini, Anna ^c   Nappi, Giuseppe ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CARBON 11; FLUMAZENIL; IODINE 123; IOMAZENIL; NEUROPROTECTIVE AGENT;

BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN METABOLISM; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DISEASE MARKER; EDITORIAL; EVOKED RESPONSE; FIBRINOLYTIC THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE PATIENT; THREE DIMENSIONAL IMAGING;

BRAIN ISCHEMIA; BRAIN MAPPING; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; COST-BENEFIT ANALYSIS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34147220028     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (54)

1. Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 1977;8:51-57
2. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke 1981;12:723-725
3. 15O positron emission tomography. Stroke 1981;12:454-459
4. Baron JC, Bousser M-G, Comar D, Soussaline F, Castaigne P. Noninvasive tomographic study of cerebral blood flow and oxygen metabolism in vivo. Eur Neurol 1981;2:273-284
5. Lenzi GL, Frackowiak RS, Jones T et al. CMRO2 and CBF by the oxygen-15 inhalation technique. Results in normal volunteers and cerebrovascular patients. Eur Neurol 1981;20:285-290
6. Baron JC. Mapping the ischaemic penumbra with PET: implications for acute stroke treatment. Cerebrovasc Dis 1999;9:193-201
7. Ginsberg MD, Pulsinelli WA. The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke. Ann Neurol 1994;36:553-554
8. Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994;36:557-565
9. Heiss WD, Rosner G. Functional recovery of cortical neurons as related to degree and duration of ischemia. Ann Neurol 1983; 14:294-301
10. Heiss WD, Graf R, Wienhard K et al. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. J Cereb Blood Flow Metab 1994;14:892-902
11. Memezawa H, Smith ML, Siesjö BK. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke 1992;23:552-559
12. Marchal G, Beaudouin V, Rioux P et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. Stroke 1996;27:599-606
13. Muir KW, Buchan A, von Kummer R, Rother J, Baron JC. Imaging of acute stroke. Lancet Neurol 2006;5:755-768
14. Furlan M, Marchal G, Viader F, Derlon JM, Baron JC. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996;40:216-226
15. Markus R, Reutens DC, Kazui S et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain 2004;127:1427-1436
16. Jaillard A, Martin CD, Garambois K, Lebas JF, Hommel M. Vicarious function within the human primary motor cortex? A longitudinal fMRI stroke study. Brain 2005;128:1122-1138
17. Cramer SC, Shah R, Juranek J, Crafton KR, Le V. Activity in the peri-infarct rim in relation to recovery from stroke. Stroke 2006; 37:111-115
18. Heiss WD, Huber M, Fink GR et al. Progressive derangement of peri-infarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992;12:193-203
19. Baron JC. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc Dis 2001;11 (Suppl 1):2-8
20. Markus R, Reutens DC, Kazui S et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain 2004;127:1427-1436
21. Wintermark M, Reichhart M, Thiran JP et al. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol 2002;51:417-432
22. Rother J, Schellinger PD, Gass A et al.; Kompetenznetzwerk Schlaganfall Study Group. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 2002;33:2438-2445
23. Muir KW, Halbert HM, Baird TA, McCormick M, Teasdale E. Visual evaluation of perfusion computed tomography in acute stroke accurately estimates infarct volume and tissue viability. J Neurol Neurosurg Psychiatry 2006;77:334-339
24. Moustafa RR, Baron JC. Imaging the penumbra in acute stroke. Curr Atheroscler Rep 2006;8:281-289
25. Fisher M. Advances in Stroke 2006. Introduction. Stroke 2007;38:214-215
26. Heiss WD, Sobesky J, Hesselmann V. Identifying thresholds for penumbra and irreversible tissue damage. Stroke 2004;35 (Suppl 1): 2671-2674
27. Guadagno JV, Warburton EA, Jones PS et al. The diffusion-weighted lesion in acute stroke: heterogeneous patterns of flow/metabolism uncoupling as assessed by quantitative positron emission tomography. Cerebrovasc Dis 2005;19:239-246
28. Sobesky J, Weber OZ, Lehnhardt FG et al. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. Stroke 2005;36:980-985
29. Heiss WD, Sorensen AG. Advances in imaging 2006. Stroke 2007;38:238-240
30. Hacke W, Albers G, Al-Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DAIS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73
31. Thomalla G, Schwark C, Sobesky J et al. MRI in Acute Stroke Study Group of the German Competence Network Stroke. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006;37:852-858
32. Thijs VN, Adami A, Neumann-Haefelin T, Moseley ME, Marks MP, Albers GW. Relationship between severity of MR perfusion deficit and DWI lesion evolution. Neurology 2001;57:1205-1211
33. Parsons MW, Barber PA, Chalk J et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28-37
34. Butcher KS, Parsons M, MacGregor L et al; EPITHET Investigators. Refining the perfusion-diffusion mismatch hypothesis. Stroke 2005;36:1153-1159
35. Neumann-Haefelin T, Wittsack HJ, Wenserski F et al. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. Stroke 1999;30:1591-1597
36. Nighoghossian N, Hermier M, Adeleine P et al. Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator. Stroke 2003;34:458-463
37. Schellinger PD, Jansen O, Fiebach JB et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 2000;31:1318-1328
38. Albers GW, Thijs VN, Wechsler L et al.; DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517
39. Fink JN, Selim MH, Kumar S, Schlaug G. Why are stroke patients excluded from tPA therapy: an analysis of patient eligibility. Neurology 2000;57:1739-1740
40. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005;36:2497-2499
41. Rajajee V, Kidwell C, Starkman S et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 2006;67:980-984
42. Boode B, Welzen V, Franke C, Van Oostenbrugge R. Estimating the number of stroke patients eligible for thrombolyic treatment if delay could be avoided. Cerebrovasc Dis 2006;23:294-298
43. Schwab M, Fitzek C, Witte OW, Isenmann S. Extending the potential of perfusion imaging with MRI to prevent major stroke. Lancet Neurol 2007;6:102-104
44. Schwartz RD, Yu X, Wagner J, Ehrmann M, Mileson BE. Cellular regulation of the benzodiazepine/GABA receptor: arachidonic acid, calcium, and cerebral ischemia. Neuropsychopharmacology 1992;6:119-125
45. Abadie P, Baron JC. In vivo studies of the central benzodiazepine receptors in the human brain with positron emission tomography. In: Diksic M, Reba RC eds Radiopharmaceuticals and Brain Pathology Studied with PET and SPECT Boca Raton; CRC Press 1991:357-379
46. Sette G, Baron JC, Young AR et al. In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anesthetized baboon. Stroke 1993;24:2046-2058
47. 2O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy. Stroke 2000;31:366-369
48. Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 2001;124:20-29
49. Heiss WD, Sobesky J, Smekal U et al. Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity: a comparative positron emission tomography/magnetic resonance imaging study in early ischemic stroke. Stroke 2004;35:1892-1898
50. Weinberger JM. Evolving therapeutic approaches to treating acute ischemic stroke. J Neurol Sci 2006;249:101-109
51. Schabitz WR, Fisher M. Perspectives on neuroprotective stroke therapy. Biochem Soc Trans 2006;34:1271-1276
52. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S; STAIR Group. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke 2007;38:245-248
53. Gonzalez RG. Imaging-guided acute ischemic stroke therapy: From "time is brain" to "physiology is brain". AJNR Am J Neuroradiol 2006;27:728-735
54. Ehlers L, Andersen G, Clausen LB, Bech M, Kjolby M. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 2007;38:85-89